The US$205 analyst price target for BDX is 37% less than our estimate of fair value In this article we are going to estimate the intrinsic value of Becton, Dickinson and Company (NYSE:BDX) by taking ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark Global Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. The fund returned -5.78% in the ...

In the last year, multiple insiders have substantially increased their holdings of Becton, Dickinson and Company (NYSE:BDX) ...

TELA Bio is suing Becton Dickinson for allegedly abusing its monopoly power in the hernia mesh market to limit competition ...

First Eagle Investments, an investment management company, released its “First Eagle Global Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Class A shares of ...

We recently published a list of 11 Best Falling Stocks to Buy According to Analysts. In this article, we are going to take a look at where Becton, Dickinson, and Company (NYSE:BDX) stands against ...

Becton, Dickinson and Company BDX, popularly known as BD, recently announced a collaboration with the Institute for ...

Becton, Dickinson, and Company (BDX), based in Franklin Lakes, New Jersey, is a leading global medical technology firm dedicated to advancing healthcare through innovative medical devices, laboratory ...

Becton, Dickinson and Company reported strong Q4 2025 results, with revenue up 8.3% and adjusted EPS up 3.9% year-over-year. Despite healthy growth, BDX's organic growth remains modest, and management ...

Valued at a market cap of $57.1 billion, Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory ...

Becton Dickinson has been sued by a rival medical device manufacturer for allegedly thwarting competition in the U.S. market ...